CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 23 enrolled
Drug / intervention
Naloxone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02976337
NCT02976337Phase 2Completed

Effect of High-dose Target-controlled Naloxone Infusion on Pain and Hyperal-gesia in Patients Following Recovery From Impacted Mandibular Third Molar Extraction. A Randomized, Placebo-controlled, Double-blind Crossover Study.

mads u werner·interventional·Posted Nov 29, 2016·Updated Feb 22, 2024

In Brief

A Phase 2 clinical trial evaluating Naloxone and Normal Saline for Healthy Subjects and 4 related conditions. Completed, enrolled 23 participants across 1 site.

Detailed Summary

Recent studies have focused on the role of endogenous opioids on central sensitization. Central sensitization is known to be impaired or altered in chronic pain conditions, as fibromyalgia or chronic tension headache. Animal studies have shown reinstatement of mechanical hypersensitivity following naloxone administration after resolution of an injury. This suggests latent sensitization. In the present study, the investigators hypothesize that a high-dose target-controlled naloxone infusion (total dose: 3.25 mg/kg) can reinstate pain and hyperalgesia 6-8 weeks after a unilateral primary open groin hernia repair procedure. The investigators aim to show that latent sensitization is present in humans and is modulated by endogenous opioids.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesDenmark

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 29, 2016
Enrollment StartOct 12, 2017
Primary CompletionNov 27, 2023
Study CompletionDec 27, 2023
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 9.6 years ago

Interventions

Naloxonedrug

active drug infusion

Normal Salinedrug

placebo comparator